• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOTRONIK SE & CO. KG EDORA 8 HF-T QP; CRT-P

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOTRONIK SE & CO. KG EDORA 8 HF-T QP; CRT-P Back to Search Results
Model Number 407137
Medical Device Problem Code Premature Elective Replacement Indicator (1483)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 04/22/2025
Type of Reportable Event Serious Injury
Event or Problem Description
This device shows eri with unexpected battery behavior.Device remains implanted.No adverse patient events were reported.Should additional information become available, this file will be updated.
 
Additional Manufacturer Narrative
The device was explanted (b)(6) 2025.The device was not returned for analysis.The analysis is therefore only based on the returned device data as well as the inspection of the quality documents associated with the manufacture of this particular device.The manufacturing process for this device was reviewed.All production steps had been performed accordingly.There was no sign of any inconsistency during the manufacturing.The final acceptance test proved the device functions to be as specified.In a next step, the returned device data was inspected.During the inspection the clinical observation could be confirmed.Analysis revealed an unexpected battery behavior, which led to the clinical observation.Based on the data available for analysis the root cause for that behavior was not determinable and can only be clarified by an analysis of the device itself.However, it cannot be excluded that this occurrence resulted from a defective component, which may compromise the ability of the device to deliver therapy.Biotronik has informed the health care professional about this analysis result, who decides, based on the patients individual circumstances and medical judgment, if the device will be exchanged.Should further relevant information or the device itself become available, this investigation will be updated and you will be informed accordingly.
 
Additional Manufacturer Narrative
The device was explanted (b)(6) 2025.The device was received and analyzed.Prior to the analysis of the device, the manufacturing process for this pacemaker was reviewed and all production steps were performed accordingly.There was no sign of any inconsistency during the manufacturing process.Particularly the final acceptance test proved the device functions to be as specified.Upon receipt, the device was interrogated showing the eri battery status, which was triggered on (b)(6) 2025.The ability of the device to deliver therapies was tested.The anti-bradycardia pacing pulses in eri mode proved to be normal and in amplitude and frequency as programmed.There was no indication of a malfunction.In a next step, the pacemaker was opened and subjected to further analysis.The visual inspection of the inner assembly showed no anomalies.The current consumption of the electrical module was directly measured and proved to be normal and as expected.There was no indication of a malfunction of the electrical module.The battery was sent to the manufacturer for further analysis.The manufacturing records of the battery were inspected, documenting that the battery parameters were within specification during the battery manufacturing.No anomalies were documented during the production process associated with this battery.The visual inspection of the battery did not reveal any external signs of damage.Further extensive analysis of the battery, including destructive analysis, identified an elevated internal battery impedance, leading to the activation of the eri battery status.In conclusion, the therapeutic functionality of the device was tested and proved to be fully functional.Further investigations revealed an elevated battery impedance as the root cause of the eri activation.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EDORA 8 HF-T QP
Common Device Name
CRT-P
Manufacturer (Section D)
BIOTRONIK SE & CO. KG
woermannkehre 1
berlin 12359
Manufacturer Contact
6024 jean road
lake oswego, OR 97035
8772459800
MDR Report Key21894430
Report Number1028232-2025-01974
Device Sequence Number14335356
Product Code NKE
UDI-Device Identifier04035479147563
UDI-Public(01)04035479147563(17)250630
Combination Product (Y/N)N
Initial Reporter StateDC
Initial Reporter CountryUS
PMA/510(K) Number
P070008
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2024
Device Explanted Year2025
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Health Professional
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup,Followup
Report Date (Section B) 01/14/2026
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Expiration Date06/30/2025
Device Model Number407137
Device Catalogue Number407137
Was Device Available for Evaluation? Device Returned to Manufacturer
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 04/22/2025
Supplement Date Received by Manufacturer04/29/2025
01/14/2026
Initial Report FDA Received Date04/23/2025
Supplement Report FDA Received Date04/29/2025
01/14/2026
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured12/15/2023
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Hospitalization; Required Intervention;
Patient Age84 YR
Patient SexFemale
-
-